BioWorld

Nov. 11, 2008

ArQule Makes Two Deals with Daiichi in Cancer

ArQule would receive $75 million in up-front cash under two deals with Japan's Daiichi Sankyo Co. Ltd. - one to develop an anticancer compound and the other to discover a new generation of kinase inhibitors for cancer. (BioWorld Today) Read More

LDL Hypothesis Alive and Well; Other Biomarkers also Valuable

Improved T-Cell Receptor Takes on all Comers of HIV Epitope

Moving from Licensing Talks to M&A can be a Tricky Step

Regulatory Hitch to Delay Solzira Filing, Milestone to XenoPort

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 29, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

Roche identifies new TREM2 agonists

BioWorld Science

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...

Plasticity, properly parsed, provides psychiatric platform

BioWorld

If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...